n-acetylcytidine has been researched along with Carcinoma, Ductal, Pancreatic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Feng, Z; Han, D; Jiang, L; Li, K; Liang, H; Liang, J; Ma, Y; Peng, C; Qin, K; Shen, B; Shi, M; Zhao, S | 1 |
| Guo, X; Jiang, W; Shen, J; Shen, S; Wan, R; Wang, C; Wang, X; Xiao, W; Yang, Q; Zhao, Q; Zong, G | 1 |
2 other study(ies) available for n-acetylcytidine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA.
Topics: Acetyltransferases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytidine; Gene Expression Regulation, Neoplastic; Humans; N-Terminal Acetyltransferases; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; RNA, Messenger; Ubiquitin-Specific Proteases | 2022 |
NAT10-mediated AXL mRNA N4-acetylcytidine modification promotes pancreatic carcinoma progression.
Topics: Carcinoma, Pancreatic Ductal; Cell Proliferation; Humans; N-Terminal Acetyltransferases; Pancreatic Neoplasms; RNA, Messenger | 2023 |